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Patients with squamous cell carcinoma of the head and neck (SCCHN) have depressed antitumour immunity. The presence of
CD4þCD25þ (Treg) cells in these patients might be, in part, responsible for downregulation of antitumour immune responses. To
evaluate the frequency and characteristics of Treg in the peripheral circulation of patients with SCCHN, we used multicolour flow
cytometry. Expression of CCR7, CD62L, z chain and Annexin V binding to Treg and non-Treg CD4þ lymphocyte populations were
evaluated. Treg were confirmed to be Foxp3þ and GITRþ. The Treg frequency was significantly elevated in patients with active
disease and those with no evidence of disease (NED) following curative therapies. Both Treg and non-Treg CD4þ T cells in patients
were significantly enriched in CCR7
  and CD62L
  cell subsets. Although Treg in patients contained a higher proportion of double
negative (CCR7
 CD62L
 ) cells, the majority of Tregs were CCR7
 CD62Lþ. The proportion of Annexin VþCD4þ T cells was
higher in patients (Po0.00005) than normal controls (NC), and Treg were significantly more sensitive to apoptosis than non-Treg in
patients and NC. Expression of z was reduced in all subsets of CD4þ T cells obtained from patients vs NC. The data suggest that
Treg in patients with SCCHN largely contain T cells with the ‘effector’ phenotype, which bind Annexin V and have low z expression,
consistent with their activation state and a rapid turnover in the peripheral circulation.
British Journal of Cancer (2005) 92, 913–920. doi:10.1038/sj.bjc.6602407 www.bjcancer.com
Published online 15 February 2005
& 2005 Cancer Research UK
Keywords: head and neck cancer; CD4þCD25þ T cells; regulatory T cells (Treg); CD4þ T-cell subsets
                                                   
Immune tolerance to self-antigens is essential for the prevention of
autoreactivity and autoimmune diseases. Currently, a subset of
CD4þ T cells expressing CD25, the IL-2 receptor a-chain, and
referred to as regulatory T cells (Treg), is considered to be
responsible for the control of autoreactive lymphocytes (Shevach,
2000). Substantial experimental evidence supports the regulatory
role of CD4þCD25þ T cells in animals and man. Thus, in
rodents, depletion of Treg resulted in the development of
autoimmune diseases and enhanced immune responses against
alloantigens and tumour-antigens, leading to rejection of trans-
planted tumours by the host immune system (Shimizu et al, 1999;
Sakaguchi et al, 2001; Sutmuller et al, 2001). This finding was not
unexpected, as a majority of known tumour-associated antigens
(TAA) are altered or overexpressed self-antigens. Therefore,
CD4þCD25þ Treg are a likely candidate for downregulation of
immune responses to these TAA. In man, Treg have been described
to be present in increased proportions among tumour-infiltrating
lymphocytes (TIL) and in the peripheral circulation of patients
with various malignancies (Woo et al, 2001; Liyanage et al, 2002;
Woo et al, 2002; Wolf et al, 2003). Based on phenotypic
characteristics, this population of lymphocytes accounts for 5–
10% of all CD4þ T cells in the peripheral circulation of healthy
individuals (e.g., Wolf et al, 2003), but in patients with cancer,
peripheral mononuclear cells (PBMC) may contain up to 25–30%
of Treg (Woo et al, 2002).
Patients with squamous cell carcinoma of the head and neck
(SCCHN) have depressed antitumour immune responses, and
tumour progression or recurrence is associated with particularly
severe immune dysfunction (Whiteside, 2004). While several
distinct mechanisms have been suggested to explain immune
unresponsiveness in these patients, including the presence of
tumour-derived inhibitory factors (e.g., PGE2), T-cell apoptosis,
inhibitory cytokines (e.g., IL-10) or excess of suppressive
macrophages, the presence of Treg at a high frequency could also
contribute to lymphocyte dysfunction, which is characteristically
and consistently observed in patients with SCCHN (Reichert et al,
1998; Hoffmann et al, 2002; Reichert et al, 2002).
The CD4þ T-cell subset of lymphocytes was previously studied
by us in patients with SCCHN (Kuss et al, 2003; Kuss et al, 2004a).
We found that the absolute count of circulating CD4þ T cells was
significantly decreased in these patients (Kuss et al, 2004a). While
the pool of naı ¨ve CD4þCD45RO-CD27þ T cells was significantly
smaller in patients than in age-matched normal controls (NC), the
pool of memory CD4þCD45ROþ T cells was significantly
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sexpanded (Kuss et al, 2003). Thus, based on the lymphocyte count,
their phenotype and the T-cell receptor excision circle (TREC)
analysis (Kuss et al, 2004b), it appears that the significant paucity
of naı ¨ve and excess of memory CD4þ T cells characterises the
subset of CD4þ T cells in SCCHN patients. However, phenotypic
characteristics or distribution of CD4þCD25 Treg among these
CD4þ cell subsets is not known.
In the present study, we investigated whether the circulating
pool of CD4þCD25þ Treg in patients with SCCHN was expanded
relative to that in NC and evaluated phenotypic and functional
characterisitics of Treg. The hypothesis tested predicted that PBMC
of these patients might be enriched in CD4þCD25þ Treg, which,
by virtue of downregulating antitumour immune functions, could
contribute to the progression or recurrence of head and neck
cancer.
MATERIALS AND METHODS
Patients and controls
Patients with head and neck cancer (HNC) were seen at the
Outpatient Otolaryngology Clinic, University of Pittsburgh Med-
ical Center (UPMC) between February and December 2003. Blood
samples were obtained from consecutive patients who signed an
informed consent form approved by the Institutional Review
Board. Normal healthy donors (NC), aged from 45 to 70 years,
were recruited among the laboratory personnel and asked to sign
the consent form prior to donating blood. The study included 24
patients with HNC and 17 NC. The clinicopathologic character-
istics of the patients included in the study are shown in Table 1.
The cohort included 16 male and eight female subjects aged from
46 to 84 years. All patients had histologically proven SCCHN, with
six cancers originating in the larynx, nine in the oral cavity, two in
the oropharynx and seven in the hypopharynx. Nine out of 24
patients had T3 or T4 disease, and 13 out of 24 had nodal
metastases. At the time of the blood draw, 14 patients showed no
evidence of disease (NED), having previously received curative
therapies, and 10 patients had active disease (AD; presurgery).
Cell isolation
Venous blood obtained from patients or controls (20–30ml) was
delivered to the laboratory within 2h of phlebotomy. Peripheral
mononuclear cells were isolated from venous blood by density
gradient sedimentation on Ficoll-Hypaque. Cells recovered from
the gradient interface were washed twice in medium, counted and
immediately used for staining.
Antibodies
The following monoclonal antibodies (mAbs): anti-CD3-ECD
(UCHT1), anti-CD4-PE (13B8.2), anti-CD8-PC5 (SFCI21Thy2D3),
anti-CD25-PC5 (B1.49.9), anti-CD62L-ECD (DREG56) and the
respective isotypes used as negative controls for surface staining
were all purchased from Beckmann Coulter (Miami, FL, USA).
Anti-CCR7-FITC mAb was purchased from R&D Systems Inc.,
Minneapolis, MN USA. For intracellular detection of TCR z chain,
anti-CD247-FITC (6B10.2) obtained from Santa Cruz Biotechno-
logy, Inc., CA, USA was used. Unlabelled polyclonal anti-Foxp3
Abs and the secondary labelled Abs were purchased from Abcam,
Ltd., Cambridge, MA, USA. Carboxyfluorescein-conjugated mAb
to glucocorticoid-induced TNF receptor (GITR) was purchased
from R & D Systems.
Annexin V apoptosis detection kit
The Annexin V-FITC Apoptosis Detection Kit was purchased from
BD PharMingen and used as recommended by the manufacturer.
Cell staining
Cells were resuspended in phosphate-buffered saline (PBS),
containing 0.1% BSA and 0.1% NaN3 to the final concentration
of 2 10
6ml
 1. Cells were stained for flow cytometry as previously
described (Kuss et al, 2003). Briefly, optimal working dilutions of
all Abs used for staining were first determined by titrations with
normal PBMC. Checkerboard titrations were used to determine
optimal dilutions of primary and secondary Abs used for indirect
staining (Foxp3). For surface staining, PBMC were incubated with
the optimal dilution of each mAb for 25min at 41C in the dark,
washed twice with PBS containing 0.1% (wv
 1) bovine serum
albumin (BSA) and 0.1% (wv
 1)N aN3 and finally fixed by adding
2% (vv
 1) paraformaldehyde (PFA) in PBS. For intracellular
staining (TCR z chain and Foxp3), surface staining for T-cell
markers was followed by two washes with the PBS/BSA/NaN3
buffer and by subsequent fixation of the PBMC in 2.5% PFA for
10min at room temperature in the dark. After another wash with
the same buffer, PBMC were permeabilised with saponin (0.1%
vv
 1 in BSA) and washed with cold saponin solution. Next, anti-z
or anti-Foxp3mAb or IgG1-FITC isotype was added to the cells.
After incubation for 25min at 41C in the dark, the cell suspension
Table 1 Clinicopathologic features of patients with SCCHN included in
the study
n
Age (years) mean (range) 58 (46–84)
Sex
Male 16
Female 8
Total 24
Tumour site
Larynx 6
Oral cavity 9
Pharynx 2
Hypopharynx 7
Tumour stage
T1 6
T2 8
T3 2
T4 7
TX 1
Nodal status
N0 11
N1 4
N2 9
Alcohol history
Yes 9
No 10
Prior 3
Unknown 2
Smoking history
Yes 13
No 3
Prior 5
Unknown 3
Status at day of blood draw
No evidence of disease 14
Active disease (presurgery) 10
SCCHN¼squamous cell carcinoma of the head and neck.
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swas washed again with 0.1% saponin, followed by another wash
with the PBS/BSA/NaN3 buffer or by a secondary Ab in the case of
Foxp3. The cells were finally fixed with 2% PFA in PBS. Stained
samples were immediately analysed by flow cytometry.
Flow cytometry analysis
Flow cytometry was performed on a Coulter Epics XL Flow-
Cytometer. Gating strategy used to identify the AnxþPI- popu-
lations of lymphocytes was previously described (Bauernhofer et al,
2003). To identify Treg populations, the gate was set to acquire
CD4þCD25
high T cells. The subsequent data analysis was
performed using the Coulter EXPO 32vl.2 analysis software.
Statistical analysis
Statistical analyses were performed using the Student’s t-test, and
P-values of o0.05 were considered significant.
RESULTS
Proportions of Treg in the circulation of patients with
SCCHN and controls
Flow cytometry analysis indicated that the patients had signifi-
cantly higher percentages of CD4þCD25þ Treg in the circulation
than NC (10.174.7 vs 5.472.7%). Representative flow cytometry
results for one patient and one normal control are shown in
Figure 1. This finding is consistent with the data reported for
patients with other epithelial cancers (Woo et al, 2001; Liyanage
et al, 2002). Among the cohort of 19 patients, eight had AD at the
time of blood draws for this study, and 11 had NED following
curative therapies (Table 1). No significant difference in the
proportion of Treg was observed between these two patient cohorts,
as illustrated in Figure 2. However, the percentage of Treg was
significantly higher in patients with AD (Po0.0008) or NED
(Po0.04) than that in NC.
Although we gated on CD4þCD25þ
high T cells, which is
considered to be the phenotype of Treg, it was necessary to
confirm their identity through expression of Foxp3 or GITR
markers (Ramsdell, 2003; Ronchetti et al, 2004). To this end,
we developed a flow-cytometry-based method with comm-
ercially available Abs to measure expression of these markers on
CD4þCD25
high T cells. In five patients with SCCHN, PBMC were
found to contain an average of 771.5% of CD4þCD25þ T cells,
571.0% of CD4þCD25þ GITRþ T cells and 6.071.3% of
CD4þCD25þFoxp3þ T cells (Table 2). These data confirm that
the large majority of CD4þCD25
high T cells express Foxp3 or
GITR, the markers associated with Tregs.
Expression of CCR7 on CD4þ T-cell subsets
Expression of the chemokine receptor CCR7 on the surface of
lymphocytes is associated with the acquisition of a migratory
phenotype (Sallusto et al, 1999; Campbell et al, 2001). Thus,
mature CD4þ T cells expressing CCR7 are able to migrate to
secondary lymphoid organs, while those lacking CCR7 are effector
cells. We, therefore, studied expression of this receptor on CD4þ
T cells of patients and NC, with special attention focused on the
subset of Treg. The expectation was that the percent of
CD4þCD25þCCR7þ cells would be lower in patients than NC,
based on our report documenting an enrichment in Treg at tumour
sites and tumour-involved lymph nodes relative to the peripheral
circulation (Albers et al, 2004). Instead, as shown in Figure 3, the
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Figure 1 Enrichment in CD4þCD25þ Treg in PBMC of a patient with SCCHN relative to a normal control. Flow cytometry was performed as
described in Materials and Methods. The gate was set to acquire bright CD4þCD25þ T cells. Isotype controls were used to set the cut-off for CD25þ vs
CD25
  cells.
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Figure 2 Frequencies of CD4þCD25þ Treg in the circulation of
patients with SCCHN and NC. The patients with AD at the time of
phlebotomy were not different from those with NED (P40.2). However,
the NED and AD patient cohorts were significantly different from NC
(Po0.04 and Po0.0008, respectively).
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spercentages of both CCR7þ and CCR7
  Treg were significantly
increased (Po0.002 and Po0.04) in the circulation of patients vs
NC. Conversely, among non-Treg CD25
 CD4þ cells, CCR7þ cells
were significantly lower in patients than NC (Po0.007), and
significant expansion of the CCR7
  subset was evident (Figure 3).
These expanded CCR7
  cells are presumably terminally differ-
entiated effector T cells (Sallusto et al, 1999). The significant shifts
observed in the content of CCR7
  and CCR7þ cells among the
CD4þ subsets of lymphocytes in patients with SCCHN are
suggestive of their distinct distribution between blood vs tissues
and perhaps of differences in the activation state or turnover rate
among functionally distinct subsets of lymphocytes.
Expression of CD62L on CD4þ T-cell subsets
Like CD27 antigen, L-selectin (CD62L) expression is lost on
mature, more differentiated T cells, which are responsible
for helper/suppressor functions performed by CD4þ T cells.
For this reason, we expected to find an increased percentage of
CD4þ T cells with the CD62L
  phenotype in the peripheral
circulation of patients with SCCHN. As seen in Figure 4, this
indeed was the case, and the expansion of CD62L
  non-Treg
Table 2 Percentages of Treg in PBMC of selected patients with SCCHN by expression of Foxp3 or GITR
Patient CD4+CD25
high (%) CD4+CD25
highGITR+ (%) CD4+CD25
highFoxp3+ (%)
1. 9
a 4
a 6
b
2. 5 5 5
3. 8.5 5 7.5
4. 6.5 3 6
5. 7.0 5 5
Mean7s.d. 7.071.5 5.071.0 6.071.3
aThe percentages of Treg were determined upon backgating on CD3+CD4+CD25
high cells following staining from surface markers, as described in Materials and Methods.
bThe
percentages of Foxp3+ cells were determined as indicated above but following cell permeabilisation and intracytoplasma staining. SCCHN¼squamous cell carcinoma of the
head and neck; GITR¼glucocorticord-induced TNF receptor; PBMC¼peripheral mononuclear cells.
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Figure 3 Altered distribution within the CD4þ T-cell subset of cells
expressing CD25 and CCR7 markers in patients with SCCHN relative to
NC. Note a significant decrease in CD4þCD25
 CCR7þ and an
enrichment in CD4þCD25
 CCR7
 , CD4þCD25þCCR7þ and
CD4þCD25þCCR7
  T cells in the circulation of patients with SCCHN
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cells expressing CD25 and CD62L markers. Note a significant decrease in
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 CD62Lþ and an enrichment in CD4þCD25
 CD62L
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CD4þCD25þCD62Lþ and CD4þCD25þCD62L
  T cells in the
circulation of patients relative to NC.
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sCD4þ T in patients with SCCHN was accompanied by a
significant concomitant decrease in the percent of CD4þ
CD25
 CD62Lþ cells. In contrast, among CD25þCD4þ Treg,
enrichment in CD62Lþ cells (Po0.005 relative to NC) exceeded
that of CD62L
  cells. These observations imply that Treg in the
circulation of patients might be at a different maturation or
activation stage than their normal counterparts. Further, the
proportion of CD4þCD25
  T cells that are CD62Lþ, that is,
belong to the naive pool, is decreased in the patients with a
concomitant enrichment in effector CD4þ T cells.
Concomitant expression of CCR7 and CD62L on Treg
Treg in patients with SCCHN contained a higher proportion of
CCR7
  and CD62L
  cells than NC (Figures 3 and 4). A loss of
CCR7 and/or CD62L markers accompanies maturation, activation
or terminal differentiation of T cells (Sallusto et al, 1999; Campbell
et al, 2001). We were, therefore, especially interested in a
concomitant loss of expression of both these markers on Treg in
the peripheral circulation of patients vs controls. Figure 5A is an
example of the four-colour flow cytometry analysis performed with
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Figure 5 In (A), multicolour flow cytometry of PBMC obtained from a representative patient with SCCHN shows an increased proportion of
CCR7
 CD62Lþ Treg relative to non-Treg CD4þCD25
  cells and to NC. In (B), expansion of CD62L
  T cells within the subset of CCR7-
CD25þCD4þ Treg in patients with SCCHN relative to NC. The gate was set on CD4þ T cells and subsets of CD25þCCR7
 CD62L
  vs
CD25þCCR7
 CD62Lþ were quantitated by four-colour flow cytometry.
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scells of a representative patient and a normal control. It shows that
the percentage of Treg is higher in the patient than in NC and that
substantially more Treg are CCR7
 CD62Lþ in the patient (43%) vs
NC (26%). Concomitantly, the patient has fewer Treg that are
CCR7þCD62Lþ than NC. Thus, T cells with the CCR7
 CD62Lþ
phenotype are the major Treg subset in patients with SCCHN. To
further focus on this subset, we next examined CD62L expression
on CD4þCD25þCCR7
  cells in patients and NC. As shown in
Figure 5B, a significant difference (Po0.03) was observed in the
ratio of double negative (CCR7
 CD62L
 )/(CCR7
 CD62Lþ)T reg
between the patients (1:2) and NC (1:5).
In aggregate, these data are consistent with the conclusion that
among Treg those with CCR7
 CD62Lþ and CCR7
 CD62L
 
phenotypes are enriched in the circulation of patients with SCCHN
relative to NC. This finding implies that more Treg in the
circulation of patients with SCCHN than in NC are terminally
differentiated and are undergoing rapid maturation and turnover.
Annexin V binding to the subsets of CD4þ T cells
We have previously reported a decrease in absolute CD4þ T-cell
counts in patients with SCCHN relative to age-matched NC (Kuss
et al, 2004a). In the cohort of patients studied here, the mean
absolute CD4þ T-cell count was 6107350mm
 3, which is
significantly lower than the normal mean count of
10057360mm
3 (Kuss et al, 2004a). It was, therefore, important
to determine whether the low absolute counts of circulating CD4þ
T cells could be explained by their apoptosis. To this end, Annexin
V (Anx V) binding to CD8þ and CD4þ circulating T cells was
evaluated by flow cytometry. In agreement with previously
published results (Hoffmann et al, 2002), we observed significantly
lower percentage of Anx VþCD4þ than CD8þ T cells in SCCHN
patients and in NC (Figure 6A). Although Annexin binding to
CD4þ T cells was significantly higher (Po0.00005) in patients
than in NC (Figure 6A), the overall proportion of CD4þ T cells
undergoing apoptosis was low, not exceeding 10% in the patients’
circulation.
We next examined Anx V binding to the CD4þ T-cell subsets,
including CD4þCD25þ and CD4þCD25
  cells, to determine
whether Treg are more or less sensitive to apoptosis than non-Treg.
As shown in Figure 6B, Anx V bound to 17.4% of Treg and 9% of
non-Treg in patients with SCCHN. In NC, 8.6% of Treg vs 3% of
non-Treg bound Anx V. Anx V binding was significantly higher
among Treg than non-Treg in the circulation of patients as well as
NC (Po0.0009). This observation suggests that Treg are more
rapidly cleared from the peripheral circulation than other CD4þ
cells, perhaps as a result of their activation and migration to tissues
to be utilised in regulatory activities. This rapid turnover of Treg
relative to non-Treg among CD4þ T cells might be a manifestation
of activation induced cell death (AICD).
Expression of f in Treg of patients with SCCHN
Expression of z chain in CD3þ T cells or their subsets is
considered to be a measure of their functional status, as it
determines the ability of T cells to signal upon TCR engagement
(Whiteside, 2004). Using flow cytometry, we initially determined
that CD8þ T cells in our cohort of patients with SCCHN had lower
expression of z (log MFI¼2.870.6) than CD4þ T cells (log
MFI¼3.470.7) as shown in Table 3. Although not statistically
significant, this difference in the MFI was consistent with higher
levels of Anx V binding to CD8þ T cells, as indicated above
(Figure 6A). Among CD4þ T cells, no difference was observed in
MFI for z expression between Treg and non-Treg (Table 3).
However, consistent with a higher percentage of Treg in the
peripheral circulation of SCCHN patients, z expression was found
to be lower in all T-cell subsets (CD4þ, CD8þ, non-Treg) in these
patients as compared to NC (Table 3). Thus, we hypothesise that
Treg, which are more numerous in patients than in NC, are
responsible for downregulation of TCR-mediated signalling in
CD8þ and non-Treg CD4þ T cells.
DISCUSSION
The Treg subset of CD4þ lymphocytes (CD4þCD25
high cells) has
assumed a considerable importance within the immunoregulatory
network both in health and disease. These cells exert suppressive
activity upon CD8þ effector and CD4þ helper T cells, and their
effects appear to be dose dependent, cell-contact dependent,
cytokine independent and antigen-nonspecific (Shevach, 2000;
Dieckmann et al, 2001; Jonuleit et al, 2001; Ng et al, 2001; Taams
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Figure 6 Annexin V (Anx V) binding to T cells. In (A), binding of Anx V
to CD4þ and CD8þ T-cell subsets in patients with SCCHN and in NC.
In (B), Anx V binding to Treg (CD4þCD25þ) vs non-Treg
(CD4þCD25
 ) T cells in patients with SCCHN and NC.
Table 3 Expression of the TCR-z chain in T-cell subsets of patients with
SCCHN and normal controls
a
CD4+CD25+ CD4+CD25
  CD8+ CD4+
TCR-f chain expression (log MFI)
NC 3.771.7 4.271.8 3.571.5 4.371.9
SCCHN 3.270.7 3.470.7 2.870.6 3.470.7
aExpression of z was measured in the various T-cell subsets by flow cytometry as
described in Materials and Methods. The data are means7s.d.
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set al, 2001;). However, more recent studies suggest that
subpopulations of Treg endowed with different regulatory func-
tions, including suppression of TAA-specific immune responses,
exist in the circulation and/or tissues of patients with cancer (Woo
et al, 2002; Shevach, 2004). Given the emerging heterogeneity of
this cell population, it is important to consider how subsets of
CD4þCD25þ cells relate to other helper T cells and to disease in
individuals with cancer.
The percentage and absolute numbers of CD4þCD25þ T cells
were reported to be increased in the peripheral circulation of
patients with various malignancies (Woo et al, 2001; Liyanage et al,
2002). In patients with SCCHN, we have recently described a
significant enrichment in CD4þCD25þ T cells in the peripheral
blood and particularly among tumour-infiltrating lymphocytes
(Albers et al, 2004). However, it now appears that Treg are a
heterogenous population within CD4þ T cells, and that a subset
of CD4þCD25þ T cells could be subdivided into different
functional subsets based on expression of novel markers such as
GITR, Foxp3 or neurophilin-1 (Cosmi et al, 2003; Ramsdell, 2003;
Bruder et al, 2004; Ronchetti et al, 2004). Further, a subset of these
cells could represent activated CD4 cells expressing the CD25þ
receptor. Taking advantage of newly available Abs to GITR and
Foxp3, we performed multiparameter flow cytometry to demon-
strate that most CD4þCD25
high T cells in the circulation of
patients with HNC express Foxp3 or glucocorticord-induced TNF
receptor (GITR). While this analysis was performed in only a small
subset of our patients, it offers support for the phenotypic analysis
of Treg subsets presented here.
The present study confirmed the enrichment in Treg among
PBMC of HNC patients and offered us an opportunity to
determine whether patients with AD had more circulating
CD4þCD25þ T cells than those with NED. Surprisingly,
both cohorts had a higher frequency of Treg than NC, and patients
presumably cured of their disease following therapy were not
different from those with tumours in respect to the proportions
of Treg in the periphery. This observation supports our
hypothesis that lymphocyte homeostasis disrupted by the presence
of tumour fails to normalise following successful therapy.
Immune abnormalities, including depressed absolute lymphocyte
counts (Kuss et al, 2004a), elevated percentages of CD8þ cells
undergoing early apoptosis (Hoffmann et al, 2002), and signalling
defects (Kuss et al, 2003), persist for weeks or years after
curative therapies in patients with NED. It appears that the
enrichment in circulating Treg is also a persistent immune
alteration that does not normalise following therapy. Nevertheless,
it is apparent from the data (Figure 2) that as a group, SCCHN
patients with AD differ most significantly from NC in the
percentage of circulating CD4þCD25þ Treg.
The maturation status of Treg and their ability to home to lymph
nodes are attributes that determine their biologic activity. We have
previously shown that the majority of CD4þ T cells in the
circulation of patients with SCCHN have a memory phenotype
(Kuss et al, 2003). Thus, it was not unexpected to find that CD4þ
T cells in patients with SCCHN were characterised by the loss of
CCR7 and L-selectin surface molecules, which are functionally
associated with cell migration into tissues and serve as phenotypic
markers for distinct stages of lymphocyte differentiation, respec-
tively. The implication of this finding is that in patients, CCR7þ
and L-selectinþ CD4þ T cells tend to localise to tissues. We have
previously reported a significant and sometimes striking enrich-
ment in CD4þCD25þ T cells among tumour-infiltrating
lymphocytes in patients with SCCHN (Albers et al, 2004), and
thus we hypothesise that these cells may preferentially localise to
tumour sites. If so, then Treg present in the circulation of SCCHN
patients might be a mix of less mature (CCR7þCD62Lþ)
lymphocytes being recruited from the naı ¨ve lymphocyte pool
and of activated or terminally differentiated Treg, which have lost
either CCR7 or CCR7 and CD62L markers. In fact, subsets of
CCR7
  and CD62L
  Treg are expanded in the circulation of
SCCHN patients relative to NC. In addition, the ratio of more
differentiated (CCR7
 CD62L
 ) to less differentiated
(CCR7
 CD62Lþ)T reg is altered in patients vs NC, because of an
increase in absolute and relative numbers of more differentiated
Treg in patients with SCCHN. This shift in Treg subsets could
be a result of selective migration to tissues and accumulation
at the tumour site or in tumour involved lymph nodes (Albers et al,
2004). Alternatively, it implies that activated Treg in the patients’
circulation undergo a rapid turnover. The observed increased
binding of Anx V by Treg is consistent with this hypothesis
and with previous reports indicating that CD4þCD25þ T cells
are more susceptible to apoptosis than other CD4þ T
cells (Salmon et al, 1994; Akbar et al, 1996; Taams et al, 2001).
Such rapid turnover of Treg in patients with SCCHN and other
cancers (i.e., entry from the naı ¨ve pool, maturation and migra-
tion into tissues) explains their enrichment in lymphoid and
tumour tissues, and the phenotype of Treg remaining in the
circulation. Based on the principle that lymphocyte activation is
accompanied by their migration into tissues and/or AICD,
reconstitution of the lymphocyte pool from naı ¨ve precursors must
be quite efficient. However, even this rapid replacement does not
seem to correct absolute CD4þ T lymphocyte count in patients
with SCCHN, which ranged from 120 to 1227mm
 3, with a mean
of 6107350 (s.d.)mm
 3 in our patient cohort, and was
significantly lower from the normal mean of 10057360mm
 3
(Po0.001).
The expansion of Treg in the circulation and tissues of patients
with cancer suggests that these cells downregulate antitumour
responses, guarding from overly vigorous responses to self-
antigens. Functional evaluations of Treg require their isolation
and titration into functionally active tumour-specific T cells. The
latter are not easily available, in humans, and are particularly
difficult to generate in patients with SCCHN, where few
immunogenic tumour-specific epitopes are available. For this
reason, we resorted to an alternative approach dependent on the
analysis of z expression, which is a signalling component of TCR in
CD4þ and CD8þ T-cell subsets. The rationale for measurements
of z expression was based on our previous data linking T-cell
dysfunction in patients with SCCHN with the absence or low
expression of the z chain (Kuss et al, 1999; Whiteside, 2004). In the
presence of Treg, which presumably downregulate functions of
other T cells, the level of z expression in these T cells is expected to
be low, thus providing some indication about activity of Treg.I t
was interesting to observe that in patients with SCCHN, various
circulating T-cell subsets had lower expression of z, as compared
to their counterparts in NC. This observation is consistent with
previous reports from our laboratory (Kuss et al, 1999). It suggests
that signalling, and therefore effector or helper functions of T cells
obtained from the circulation of patients with SCCHN are
compromised in signalling via TCR, possibly because of the
presence of Treg.
Finally, it has to be conceded that further analysis of the
functional potential of Treg will be necessary to elucidate their
impact on disease progression. The current study, performed
largely by using multicolour flow cytometry with a small number
of blood samples obtained from patients with SCCHN is obviously
limited by the availability of cells. Nevertheless, it illustrates the
importance of Treg in defining the immune profile of patients with
cancer and emphasises the role of these cells in downregulating
functions of other T-cell subsets.
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